INVESTIGATION OF PRESENT CONDITION OF HBV ＆ HCV INFECTION FOR CONTROL AND PREVENTION OF HBV ＆ HCV INFECTION IN HEMODIALYSIS PATIENTS

我们调查了血液透析机构中HBV和HCV感染的现状，并试图控制和预防HBV和HCV感染，我们在这22个月内对我州9个血液透析机构的2，275名患者进行了调查，现在继续调查。在本研究期间，我们每3个月抽取所有患者的血液。患者平均年龄为60 ~ 61岁。1）HCV感染率：HCV抗体阳性率为13 ~ 26.2%，各机构间略有差异。HCV抗体阳性率平均为15%。HCV抗体阳性患者中HCV携带者的比例约为74%。2）HCV的发病率：在这2，275例患者中，有1，668例患者在首次检测时抗HCV阴性，此后对其进行了随访。10例患者血清抗-HCV阳转，均为HCVRNA阳性。因此，HCV病毒血症的发病率为0.42/100人-年。3）HCV感染者HCV核心肽的变化：对272例HCV感染者进行了3次采血后HCV核心肽的动态变化检测。16%的携带者可检测到HCV核心肽发生较大变化。尤其是男性携带者，HCV核心肽的变化比女性携带者更大。在血液透析机构中，需要通过检测HCV携带者的HCV核心肽来控制HCV感染。

We have investigated the present condition of HBV ＆ HCV infection in hemodialysis facilities and try to control and prevent HBV ＆ HCV infection.We have investigated 2,275 patients in 9 hemodialysis facilities in our prefecture for these 22 months and now continue to investigate them. We have drawn blood of all patients every 3 months during this investigation. The average age of patients is 60 〜 61 years old.1) Prevalence of HCV :HCV antibody positive rate is 13 〜 26.2% and is different slightly in facilities. The average of HCV Ab positive rate is 15%. The rate of HCV carriers is about 74% of HCV Ab positive patients.2) Incidence of HCV :In this 2,275 patients, 1,668 patients were negative for anti HCV at the first testing, and they were followed thereafter. Seroconversion to anti HCV was found in 10 patients and all these 10 patients were positive for HCV RNA. Thus, the incidence rate of HCV viremia was 0.42 per 100 person-years. Of these seroconverted patients, all were found to increase the titers of anti HCV as same as other HCV carriers.3) The change of HCV core peptide in HCV carriers :We checked the serial change of HCV core peptide of 272 HCV carriers who could be drawn blood 3 times during this investigation. Great change of HCV core peptide could be investigated in 16% of carriers. Especially, in male carriers, greater change of HCV core peptide could be investigated than in female. In hemodialysis facilities, we need to control HCV infection as checking HCV core peptide of HCV carriers.